Abstract

Cardiovascular complications are the leading cause of increasing and premature mortality in diabetic patients. Matrix metalloproteinases (MMPs) play an important role in the development and progression of vascular lesions. Matrix metalloproteinases are members of endopeptidases and are capable of degrading many extracellular matrix components. Results of recent studies indicated that non-pharmacological and pharmacological treatment of diabetes influenced disturbed system of metalloproteinases and their inhibitors. Clinical trials are being performed in hope that the selective MMP inhibitors reduce the progression of pathological vascular remodeling in diabetes. Further basic and clinical research is required to confirm hypothesis.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.